Long-term immunogenicity assessment of a DTaP-IPV//PRP-T vaccine given at 2, 4, 6 and 18-19 months of age, and immunogenicity and safety of a DTaP-IPV vaccine given as a booster dose at 4 to 6 years of age in Thai children

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 43, Issue 3, 2012, Pages 687-698

  Pancharoen, Chitsanu ^a   Chotpitayasunondh, Tawee ^b   Chuenkitmongkol, Sunate ^c   Ortiz, Esteban ^d  

^a KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^b QUEEN SIRIKIT NATIONAL INSTITUTE OF CHILD HEALTH   (Thailand)

^c Sanofi Pasteur   (Thailand)

^d SANOFI PASTEUR   (France)

Author keywords

Acellular pertussis; Booster vaccination; Hib conjugate vaccine; Immunogenicity; Inactivated polio vaccine; Pentavalent combined vaccine; Safety; Tetravalent combined vaccine

Indexed keywords

EID: 84868156722     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Bonmarin I, Levy-Bruhl D, Baron S, Guiso N, Njamkepo E, Caro V. Pertussis surveillance in French hospitals: results from a 10 year period. Euro Surveill 2007; 12.
2. Bonnet MC, Dutta A. World wide experience with inactivated poliovirus vaccine. Vaccine 2008; 26: 4978-83.
3. Carlsson RM, Claesson BA, Fagerlund E, Knutsson N, Lundin C. Antibody persistence in five-year-old children who received a pentavalent combination vaccine in infancy. Pediatr Infect Dis J 2002; 21: 535-41.
4. Carlsson RM, Trollfors B. Control of pertussis- lessons learnt from a 10-year surveillance programme in Sweden. Vaccine 2009; 27: 5709-18.
5. Centers for Disease Control and Prevention (CDCP). Recommended childhood immunization schedule - United States, 2001. MMWR 2001; 50: 1-3.
6. Centers for Disease Control and Prevention (CDCP). Update on vaccine-derived polioviruses-worldwide, January 2006-August 2007. MMWR Morb Mortal Wkly Rep 2007; 56: 996-1001.
7. Chotpitayasunondh T, Thisyakorn U, Pancharoen C, Chuenkitmongkol S, Ortiz E. Antibody persistence after primary and booster doses of a pentavalent vaccine against diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b vaccine among Thai children at 18-19 months of age. Southeast Asian J Trop Med Public Health 2012; 43: 442-54.
8. Edwards K, Decker M. Pertussis vaccines. In: Plotkin S, Orenstein W, Offit PA, eds. Vaccines. 5 ed. Philadelphia: Saunders, 2008: 467-517.
9. Esposito S, Agliardi T, Giammanco A, et al. Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection. Infect Immun 2001; 69: 4516-20.
10. Global Polio Eradication Initiative (GPEI). Wild poliovirus weekly update. Geneva: GPEI, 2011. [Cited 2011 Nov 23]. Available from: URL: http://www.polioeradication.org/ Dataandmonitoring/Poliothisweek.aspx
11. Grimprel E, Begue P, Anjak I, Njamkepo E, Francois P, Guiso N. Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France. Clin Diagn Lab Immunol 1996; 3: 93-7.
12. Guiso N, Njamkepo E, Vie lS, et al. Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life. Vaccine 2007; 25: 1390-7.
13. Guiso N, Liese J, Plotkin S. The Global Pertussis Initiative: Meeting report from the Fourth Regional Roundtable Meeting, France, 14- 15 April, 2010. Hum Vaccin 2011; 7: 481-8.
14. Gustafsson L, Hessel L, Storsaeter J, Olin P. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics 2006; 118: 978-84.
15. Hellenbrand W, Beier D, Jensen E, et al. The epidemiology of pertussis in Germany: past and present. BMC Infect Dis 2009; 9: 22.
16. Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt HJ, von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J 2006; 25: 507-12.
17. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005; 59: 587-635.
18. Langue J, Matisse N, Pacoret P, Undreiner F, Boisnard F, Soubeyrand B. Persistence of antibodies at 5-6 years of age for children who had received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance of second booster with a tetravalent acellular vaccine at 5-6 years of age. Vaccine 2004; 22: 1406-14.
19. Mallet E, Matisse N, Mathieu N, Langue J, Boisnard F, Soubeyrand B. Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5-6-year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster. Vaccine 2004; 22: 1415-22.
20. Meyer C, Habermehl P, Knuf M, Hoet B, Wolter J, Zepp F. Immunogenicity and reactogenicity of acellular pertussis booster vaccines in children: standard pediatric versus a reduced-antigen content formulation. Hum Vaccin 2008; 4: 203-9.
21. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998a; 17: 857-72.
22. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998b; 17: 873-90.
23. Pichichero M, Edwards K, Anderson EL, et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics 2000; 105: e11.
24. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010; 17: 1055-65.
25. Plotkin S, Vidor E. Poliovirus vaccine - inactivated. In: Plotkin S, Orenstein W, Offitt P, eds. Vaccines. 5th ed. Philadelphia: WB, Saunders, 2009.
26. Plotkin SA, Liese J, Madhi SA, Ortiz E. A DTaP-IPV//PRP approximately T vaccine (Pentaxim): a review of 16 years' clinical experience. Expert Rev Vaccines 2011; 10: 981-1005.
27. Poovorawan Y, Hutagalung Y, Chongsrisawat V, Thaemboonlers A, Lefevre I. Long-term antibody persistence in children primed and boosted with a DTPw-HBV vaccine at 2, 4, 6, 18 months of age. Vaccine 2008; 26: 1535-40.
28. Rendi-Wagner P, Paulke-Korinek M, Stanek G, Khanakah G, Kollaritsch H. Impact of a pertussis booster vaccination program in adolescents and adults on the epidemio-logy of pertussis in Austria. Pediatr Infect Dis J 2007; 26: 806-10.
29. Rennels MB. Need for polio boosters after age two years. Vaccine 2009; 27: 179-80.
30. Swedish Institute for Infectious Disease Control (SIIDC). Eleven year report - Pertussis surveillance in Sweden. Progress report October 1 1997 - December 31 2008, with an executive summary. Solna: SIIDC, 2009. [Cited 2011 Nov 23]. Available from: URL: http://www.smittskyddsinstitutet.se/upload/Publikationer/smirapport-06-2009. pdf
31. Taranger J, Trollfors B, Lagergard T, et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis 2000; 181: 1010-3.
32. Thisyakorn U, Chotpitayasunondh T, Pancharoen C, Chuenkitmongkol S, Ortiz E. Evaluation of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim) at 2, 4, and 6 months of age plus hepatitis B vaccine at birth, 2, and 6 months of age in infants in Thailand. Southeast Asian J Trop Med Public Health 2010; 41: 450-62.
33. World Health Organization (WHO). Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries. Weekly Epidemiol Rec 2003; 78: 241-52.
34. World Health Organization (WHO). Inactivated poliovirus vaccine following oral poliovirus vaccine cessation. Weekly Epidemiol Rec 2006; 81: 137-44.
35. World Health Organization (WHO). Pertussis position paper. Weekly Epidemiol Rec 2010; 85: 385-400.
36. World Health Organization (WHO). United Nations prequalified vaccines 2011. Geneva: WHO, 2011. [Cited 2011 Nov 23]. Available from: URL: http://www.who.int/ immunization_standards/vaccine_quality/ PQ_vaccine_list_en/en/index.html